Company Overview
| Stock Name | 歌禮製藥有限公司 - B |
|---|---|
| Stock Code | 01672 |
| Company Full Name | 歌禮製藥有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 公司主要於中國從事生物制品研發。 |
| Listing Date | 2018-08-01 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省杭州市濱江區江漢路1785號雙城國際4幢18層 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.ascletis.com |
| Share Registrar | |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 14.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 18.8% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 313,796,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 14.0 |
|---|---|
| First Day Open | HK$ 14.8 |
| First Day Change | 19.57% |
| First Day Volume | 82741300.0 |
| First Day Turnover | 1179890000.0 |
Use of Proceeds
| Use of Proceeds | 1、約30.0%或892.8百萬港元將用于我們核心產品線的持續研發； 2、約25.0%或744.0百萬港元將用于戈諾衛及拉維達韋商業化； 3、約15.0%或446.4百萬港元將用于尋求新在研藥物的引進許可，盡管我們截至最后實際可行日期尚未物色到任何潛在目標； 4、約10.0%或297.6百萬港元將用于通過啟動及進行臨床試驗進行ASC21的研發； 5、約10.0%或297.6百萬港元將用于支持我們的研發基礎設施及HBV及NASH發現階段兩個內部藥物計劃的早期開發； 6、約10%或297.6百萬港元將用于我們的營運資金及作其他一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
摩根士丹利亚洲有限公司 CE AAD291
高盛（亚洲）有限责任公司 CE ACC536
招商证券（香港）有限公司 CE AAI650
Overall Coordinators (3)
摩根士丹利亚洲有限公司 CE AAD291
高盛（亚洲）有限责任公司 CE ACC536
招商证券（香港）有限公司 CE AAI650
Joint Bookrunners (3)
摩根士丹利亚洲有限公司 CE AAD291
高盛（亚洲）有限责任公司 CE ACC536
招商证券（香港）有限公司 CE AAI650
Joint Lead Managers (3)
摩根士丹利亚洲有限公司 CE AAD291
高盛（亚洲）有限责任公司 CE ACC536
招商证券（香港）有限公司 CE AAI650
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | GIC Private Limited | 588,588,000 HKD | — | 18.76% | — | 6 months | 2019-02-01 |
Directors & Management
| Chairman | 吳勁梓 |
|---|---|
| Company Secretary | 鐘明輝 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 吳勁梓(55.15%);傅唯(5.90%);JJW11 Limited(5.85%) |
|---|
